Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-23-015944
Filing Date
2023-09-22
Accepted
2023-09-22 16:06:15
Documents
6

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20230922xdefa14a.htm DEFA14A 55591
2 GRAPHIC tmb-20230922xdefa14a_a003.jpg GRAPHIC 6813
3 GRAPHIC tmb-20230922xdefa14a_a004.jpg GRAPHIC 9002
4 GRAPHIC tmb-20230922xdefa14a_a005.jpg GRAPHIC 2366
5 GRAPHIC tmb-20230922xdefa14a_bg001.jpg GRAPHIC 122234
6 GRAPHIC tmb-20230922xdefa14a_bg002.jpg GRAPHIC 124646
  Complete submission text file 0001558370-23-015944.txt   422654
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-14778 | Film No.: 231271770
SIC: 2834 Pharmaceutical Preparations